Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphoma
University of Washington has registered a Phase 2 trial combining Incyte's tafasitamab with rituximab in untreated follicular lymphoma, with Incyte as collaborator.
This week brought a single new trial registration involving Incyte's tafasitamab.
- "TREND-FL" is a Phase 2 trial testing tafasitamab and rituximab in patients with Classic, Grade 1, Grade 2, and Grade 3a Follicular Lymphoma1, sponsored by the University of Washington with Incyte Corporation as collaborator. The study status is not yet recruiting, with a primary completion date estimated for 2030-10-311, and an estimated enrollment of 30 participants1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.